Related references
Note: Only part of the references are listed.A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells
Joan Fernando et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer
Q. H. Miow et al.
ONCOGENE (2015)
Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling
Mari Masuda et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer
P. Zhang et al.
CELL DEATH & DISEASE (2014)
CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d
Hsiao-Chi Tsai et al.
ONCOTARGET (2014)
Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer
Yuji Toiyama et al.
CARCINOGENESIS (2013)
Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin α6β4 and Notch1/Jagged2 signaling pathway
Ya-Ling Hsu et al.
CARCINOGENESIS (2013)
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo
Mian Xie et al.
EUROPEAN JOURNAL OF CANCER (2013)
Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis
Xiang-Dan Cui et al.
HEPATOLOGY (2013)
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Tokuzo Arao et al.
HEPATOLOGY (2013)
B-crystallin complexes with 14-3-3 to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
Xiao-Yong Huang et al.
HEPATOLOGY (2013)
Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer
R. Saito et al.
ONCOGENE (2013)
VCP Phosphorylation-Dependent Interaction Partners Prevent Apoptosis in Helicobacter pylori-Infected Gastric Epithelial Cells
Cheng-Chou Yu et al.
PLOS ONE (2013)
Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease
Y-M Li et al.
CELL DEATH & DISEASE (2013)
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
S. Hagiwara et al.
BRITISH JOURNAL OF CANCER (2012)
Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Ling-Yen Chung et al.
CLINICAL CANCER RESEARCH (2012)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection
Han Wu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration
Changhua Zhou et al.
BREAST CANCER RESEARCH (2012)
Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer
Mikel Garcia-Marcos et al.
FASEB JOURNAL (2011)
Novel Roles of Galectin-1 in Hepatocellular Carcinoma Cell Adhesion, Polarization, and In Vivo Tumor Growth
Maria V. Espelt et al.
HEPATOLOGY (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance
Colin D. White et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
Koji Miyahara et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Kuen-Feng Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Comparative proteomics analysis of human osteosarcomas and benign tumor of bone
Y. Li et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
Da-Liang Ou et al.
CANCER RESEARCH (2010)
Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells
Xu-Yun Zhao et al.
CARCINOGENESIS (2010)
Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer
Wei Yang et al.
JOURNAL OF PROTEOME RESEARCH (2010)
Annexin A1 regulates TGF-β signaling and promotes metastasis formation of basal-like breast cancer cells
Marjo de Graauw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis
Liang Weng et al.
CANCER SCIENCE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Evidence of galectin-1 involvement in glioma chemoresistance
Marie Le Mercier et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2008)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cancer proteomics and its application to discovery of therapy response markers in human cancer
Laura Smith et al.
CANCER (2006)
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation
JA Díaz-González et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic prediction and treatment strategy in hepatocellular carcinoma
J Bruix et al.
HEPATOLOGY (2002)
Share Paper
